Is it possible to discontinue imatinib m
โ
Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria
๐
Article
๐
2009
๐
Elsevier Science
๐
English
โ 111 KB
Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o